Johnson & Johnson
Researches, manufactures, and sells prescription medicines for oncology, immunology, and other conditions, plus surgical equipment, orthopaedic devices, and contact lenses globally.
As of Oct 16, 2026
Summary
Johnson & Johnson is a diversified healthcare company operating across pharmaceuticals, medical devices, and consumer health. The stock is trading at $255.56 with a bearish technical bias, having declined 5.4% over the past month despite gaining 36.7% over the year. The company carries a market capitalisation of $610 billion.
Price history
As of Oct 16, 2026
Performance
+0.90%
-2.25%
-5.43%
+3.22%
+25.48%
+36.69%
As of Oct 16, 2026
Technical indicators
- 43.8
- -0.74Bearish
- 50: 264.92 · 200: 242.3
- $251.17 / $262.85
Technical Bias
Bearish lean
Johnson & Johnson's technical setup leans bearish right now: MACD sits negative at -0.74, while RSI and moving averages read neutral. This derived technical read—not a recommendation—reflects mixed momentum with downside bias rather than a compelling signal either way.
A transparent read of the indicators below — not a prediction or recommendation.
As of Oct 16, 2026
Fundamentals
- $610B
- 38.43
- $6.59
- 16.20%
- +5.9%
- $19.7B
- 0.21
- $180.59 – $281.07
- 2.11%
- Nov 24, 2026
- —
As of Oct 18, 2026
Upcoming catalysts
- Ex-dividend date
As of Oct 18, 2026
Latest news
As of Oct 18, 2026
MonkeyTrade's Take on Johnson & Johnson
Short-term outlook
The short-term lean on Johnson & Johnson tilts bearish: the MACD is negative, the shares sit below their 50-day average of $264.92, and the stock is down 5.4% over the past month. Watch $251.17 — a break below would reinforce the downside case, while a reclaim of $262.85 would be the signal that buyers are regaining control. With RSI at 43.8, there's no extreme yet, so the next move through either level should set the tone for coming weeks.
Medium-term outlook
Johnson & Johnson's steady 5.9% revenue growth and 16.2% profit margin sit oddly alongside a stretched 38.43 P/E, suggesting the shares are priced for more than the current trend supports, and the bearish technical lean echoes that caution. For the next few quarters, the balance tilts toward consolidation rather than upside. A re-acceleration in revenue growth would be the development that flips this read.
Key risks
- A price-to-earnings ratio of 38.43 sits well above typical market averages, which leaves less room for error if growth disappoints.
- Healthcare stocks have shown recent weakness, with sector-wide declines noted on multiple trading days.
- The stock is trading closer to its 52-week high of $281.07 than its low of $180.59, which can mean less room to absorb negative surprises.
- Direct comparisons to peers like UnitedHealth highlight that investors are actively weighing Johnson & Johnson against competitors, adding relative valuation pressure.
About Johnson & Johnson
Johnson & Johnson is one of the world's largest healthcare companies, listed on the NYSE under the ticker JNJ. Operating in the drug manufacturing industry within the broader healthcare sector, the company carries a market capitalisation of $610B, reflecting its scale and standing as a major, established player in pharmaceuticals.
Looking at its key figures, Johnson & Johnson trades on a price-to-earnings ratio of 38.43, a measure of how the market is valuing its earnings relative to its share price. The stock also offers a dividend yield of +2.1%, giving an indication of the income return shareholders receive relative to the share price. Together, these figures offer a snapshot of how the market currently views the company's valuation and shareholder returns.
How to trade Johnson & Johnson
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.